Awaiting development: Guidance and quality standards

Showing 161 to 170 of 344

Guidance and quality standards awaiting development
Title	Type
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Luspatercept for treating haemoglobin H disease [ID6714]	Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]	Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]	Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]	Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance